Auxilium Pharmaceuticals Inc.
) announced positive results from a phase IIa study on Xiaflex
(collagenase clostridium histolyticum or CCH), being evaluated for
the treatment of dematous fibrosclerotic panniculopathy (EFP),
which is commonly known as cellulite. The company's shares jumped
4.39% on the news.
According to the data presented by the Auxilium Pharma, all
three doses (low (0.06mg), mid (0.48mg) and high (0.84mg))
evaluated in the randomized, double-blind study showed an
improvement in the appearance of the cellulite. The company said
that a statistically significant improvement in the appearance of
the cellulite was observed in the mid and high dosage groups
compared to placebo.
In the study, 68% of the both the mid and high dose patients were
reported to be satisfied or very satisfied compared to the placebo
arm patients (34%). The candidate was also found to be
On the back of encouraging data, Auxilium Pharma intends to
initiate a phase IIb clinical trial in the second quarter of 2015.
Xiaflex is currently approved for Dupuytren's contracture and
Peyronie's. We are encouraged by Auxilium Pharma's efforts to
expand Xiaflex's label. Xiaflex generated sales of $26.3 million in
the U.S in the second quarter of 2014, up 75.3% from the year-ago
period. Approval for additional indications will boost sales of the
drug. Xiaflex is currently in phase II development for frozen
shoulder syndrome besides cellulite. Meanwhile, the FDA will be
deciding on Xiaflex's label expansion for the treatment of two
Dupuytren's contracture cords concurrently in October.
Auxilium Pharma is a Zacks Rank #4 (Sell) stock. Some better-ranked
stocks in the healthcare sector include Endo International plc (
), Hyperion Therapeutics, Inc. (
) and United Therapeutics Corp. (
). All three carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
AUXILIUM PHARMA (AUXL): Free Stock Analysis
HYPERION THERAP (HPTX): Free Stock Analysis
UTD THERAPEUTIC (UTHR): Free Stock Analysis
ENDO INTL PLC (ENDP): Free Stock Analysis
To read this article on Zacks.com click here.